Ferdinandos Skoulidis, MD, PhD, MRCP, Discusses Exciting Research in the Lung Cancer Field From ASCO 2021
Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Ferdinandos Skoulidis, MD, PhD, MRCP, an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, to discuss exciting data from the meeting in the field of lung cancer.
In particular, he focuses in on agents that have been developed to treat patients who have EGFR-mutant lung cancer tumors.
Transcript:
Some of the findings [were] presented by [Joshua M. Bauml, MD] of Penn Medicine, in the following session regarding the activity of amivantamab-vmjw [Rybrevant] in combination with lazertinib [YH25448] for osimertinib [Tagrisso]–relapsed, chemotherapy-naïve, EGFR-mutant non–small cell lung cancer [NCT02609776].1 [Another study examined the] activity of patritumab deruxtecan.2 [Both] are particularly exciting studies that push the boundaries further in another prevalent molecular subset of lung adenocarcinoma—EGFR-mutant tumors.
References
- Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol. 2021;39(suppl 15):9006. doi:10.1200/JCO.2021.39.15_suppl.9006
- Janne PA, Baik CS, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):9007. doi:10.1200/JCO.2021.39.15_suppl.9007
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
